Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil

Anti-Cancer Drugs ◽

10.1097/01.cad.0000127144.73043.57 ◽

2004 ◽

Vol 15 (5) ◽

pp. 473-477 ◽

Author(s):

Joerg Thomas Hartmann ◽

Karin Oechsle ◽

Elke J??ger ◽

Hans Edgar Reis ◽

Cornelie Haag ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase ◽

Line Therapy ◽

Third Line Therapy ◽

Download Full-text

276 Promising activity with capecitabine and mitomycin C (MMC) as third line therapy for patients with metastatic colorectal cancer (MCRC) resistant to fluorouracil (5-FU) and irinotecan: results of a phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90309-0 ◽

2003 ◽

Vol 1 (5) ◽

pp. S85

Author(s):

J.L.B. Dickson ◽

S. Rao ◽

M.E. Hill ◽

T.J. Price ◽

A.R. Norman ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Mitomycin C ◽

Phase Ii ◽

Phase Ii Study ◽

Line Therapy ◽

Third Line Therapy ◽

Download Full-text

P-052 Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdw199.50 ◽

2016 ◽

Vol 27 ◽

pp. ii16 ◽

Author(s):

H. Osumi ◽

E. Shinozaki ◽

M. Suenaga ◽

S. Matsusaka ◽

I. Nakayama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Line Therapy ◽

Third Line Therapy ◽

Download Full-text

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

European Journal of Cancer ◽

10.1016/s0959-8049(01)81497-0 ◽

2001 ◽

Vol 37 ◽

pp. S272 ◽

Author(s):

C. Twelves ◽

C. Butts ◽

J. Cassidy ◽

Th. Conroy ◽

F. DeBraud ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Preliminary Results ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

International Multicenter

Download Full-text

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text

‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study

European Journal of Cancer ◽

10.1016/s0959-8049(99)80667-4 ◽

1999 ◽

Vol 35 ◽

pp. S75 ◽

Author(s):

A. Schulz ◽

D. Garfield ◽

W. Berry ◽

D. Gordon ◽

C. Lowery ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Study ◽

Line Therapy ◽

Third Line Therapy ◽

Download Full-text

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Case Medical Research ◽

10.31525/ct1-nct04179084 ◽

2019 ◽

Author(s):

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Line Therapy ◽

Third Line Therapy ◽

Download Full-text

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

10.1186/s12885-015-1685-z ◽

2015 ◽

Vol 15 (1) ◽

Author(s):

Hitoshi Soda ◽

Hiromichi Maeda ◽

Junichi Hasegawa ◽

Takao Takahashi ◽

Shoichi Hazama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line Therapy ◽

Multicenter Phase ◽

Download Full-text

Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

Annals of Oncology ◽

10.1093/annonc/mdx393.047 ◽

2017 ◽

Vol 28 ◽

pp. v177

Author(s):

Y. Mori ◽

N. Suzuki ◽

T. Nagasaka ◽

H. Tanioka ◽

Y. Iwamoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text

A Phase II Study of Tri-Weekly Panitumumab Regimen as a Third-Line Therapy for Patients with Advanced Colorectal Cancer

Annals of Oncology ◽

10.1016/s0923-7534(20)32508-4 ◽

2012 ◽

Vol 23 ◽

pp. xi160

Author(s):

A. Goto ◽

Y. Ichikawa ◽

T. Shimamura ◽

M. Kijima ◽

I. Endo

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Study ◽

Line Therapy ◽

Third Line Therapy ◽

Download Full-text

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01473-3 ◽

2019 ◽

Vol 24 (10) ◽

pp. 1223-1230 ◽

Author(s):

Nobuaki Suzuki ◽

Shoichi Hazama ◽

Takeshi Nagasaka ◽

Hiroaki Tanioka ◽

Yasuo Iwamoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text